Bio Preventive Medicine (BPM) is an innovative and clinical staged biotech company, focusing on high value added molecular diagnostic product development among the fields of disease’s early detection and prevention. Invested mainly by angels and Top Taiwan Venture Capital, BPM, an ITRI spin-off startup, was founded in Q3 2014 with headquarter in Hsinchu, Taiwan.
With its core technologies derived from a National Biomarker Project, which has been sponsored by MOEA for many years, BPM launched its first product “DNlite” in 2014. DNlite Test, a non-invasive urinary test for monitoring the progression of Diabetic Nephropathy, will be an effective tool for managing renal complications in diabetes and help patients get rid of the nightmare of dialysis. In addition to technology for diabetic nephropathy, the proprietary technologies of BPM also include biomarker-based diagnostic technology for other chronic diseases and oncology.
Being together with growing trend of preventive medicine, it will promote fast growth of BPM, offering total solution in prevention, screening, monitoring on chronic diseases and cancers management. BPM has demonstrated excellence with domain expertise in translational research and IVD development, opening a new era of precision medicine.
BPM's vision is to promote preventive medicine and reduce healthcare burden with biomarker-related technologies. Our mission is poised to develop novel and high valued diagnostic product, including IVD and lab service. We enable pharmaceutical partners to realize the clinical trial efficiency in drug development through use of clinically proven biomarkers. We also exploit our expertise in assay platform development by partnering and collaborating with leading industry organizations.